Patent Number: 7,709,002

Title: Mutated ras peptides for generation of CD8.sup.+Cytotoxic T lymphocytes

Abstract: Mutant ras oncogene peptides may induce specific anti-ras cellular immune responses in vaccinated patients. Moreover, a human CD8+ CTL epitope(s) reflecting a specific point mutation in the K-ras oncogene at codon 12 was identified. The mutant ras peptide has implications for both active and passive immunotherapies in selected carcinoma patients. A nested 10-mer peptide was identified [i.e., ras5-14(Asp12)], which was shown to bind to HLA-A2 and display specific functional capacity for expansion of the in-vivo-primed CD8+ CTL precursors.

Inventors: Schlom; Jeffrey (Potomac, MD), Abrams; Scott (Amherst, NY)

Assignee: The United States of America as represented by the Department of Health and Human Services

International Classification: A61K 39/00 (20060101); A61K 39/04 (20060101); A61K 39/385 (20060101); A61K 39/39 (20060101); A61K 45/00 (20060101); C07K 4/00 (20060101)

Expiration Date: 5/04/12018